Related Experiment Video
Updated: Apr 21, 2026
07:57
Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
Published on: December 8, 2011
33.2K
Local Probiotic Therapy for Vaginal Candida albicans Infections
Stefan Miladinov Kovachev1, Rossitza Stefanova Vatcheva-Dobrevska
1Department of Gynecology, Military Medical Academy, G. Sofijsky Str. 3, 1600, Sofia, Bulgaria, stkovachev@abv.bg.
Probiotics and Antimicrobial Proteins
|November 3, 2014
Summary
Standard azole therapy for vaginal yeast infections shows high recurrence rates due to resistance. Combining azoles with probiotics significantly improves treatment efficacy and reduces persistent symptoms.
Area of Science:
- Gynecology
- Microbiology
- Pharmacology
Background:
- Recurrent vaginal candidiasis caused by Candida albicans presents a significant clinical challenge.
- High rates of azole resistance (up to 15%) contribute to treatment failures and relapses.
Purpose of the Study:
- To evaluate the clinical and microbiological effectiveness of standard azole therapy for vaginal candidiasis.
- To assess the impact of combining azole therapy with local probiotic application on treatment outcomes and vaginal microbiota.
Main Methods:
- A randomized study involving 436 women diagnosed with vaginal candidiasis.
- Group 1 received standard azole therapy (fluconazole and fenticonazole).
- Group 2 received azole therapy followed by a vaginal probiotic containing multiple Lactobacillus species and Streptococcus thermophilus.
Main Results:
- Azole monotherapy demonstrated over 30% Candida albicans resistance and persistent clinical symptoms in 79.7% of patients.
- The combination therapy group showed a significant reduction in clinical complaints to 31.1%.
- Microbiological efficacy improved in the combination group, with success rates increasing from 93.7% to 95.2%.
Conclusions:
- Local probiotic application following azole treatment enhances therapeutic efficacy for vaginal Candida albicans infections.
- This combined approach shows potential in preventing treatment relapse and managing azole-resistant cases.
Related Concept Videos
01:28Microbiota of the Urogenital Tract
50
The human urogenital system, once thought to be sterile in healthy individuals, is now recognized as a complex microbial habitat. Advancements in molecular sequencing techniques have revealed that even in healthy adults, the kidneys and bladder harbor microbial populations similar to those found in the distal urethra, albeit in much lower abundance. These resident microorganisms, while generally innocuous, can become opportunistic pathogens under conditions that alter the urogenital...
50
01:22Probiotics
272
Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
272
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.4K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.4K
01:18Surface Membrane Barriers
2.9K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
2.9K
01:15Antifungal Agents
110
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
110
01:17Drugs for Treatment of Diarrhea-Predominant IBS
990
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
990